Biohaven CEO says drug approval is ‘monumental’ for migraine patients

Business

In this article

Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.

The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.

“This is a monumental approval for Biohaven and patients with migraine,” Coric said in a “Mad Money” interview with Jim Cramer.

“I’ve been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,” Coric said. “This is going to change the paradigm in which migraine is treated.”

The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg and model Khloe Kardashian to promote the therapy.

Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com

Articles You May Like

Bitcoin billionaire Sam Bankman-Fried bails out embattled crypto firms BlockFi and Voyager
Stocks making the biggest moves premarket: JD.com, Roku, Alibaba and more
Fanatics is in talks to buy sports betting company Tipico, sources say
Black personal finance influencers are making financial freedom a focus this Juneteenth
Carbon Taxes and the Future of Green Tax Reform